Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recent news and posts

Tags

Use tags to find relevant records
3D printed implants
Ablation methods
Allogeneic mesenchymal stem cells
Ambulatory ECG monitoring
Aortic abdominal aneurysm
Aortic root replacement
Arthroplasty
Arthroscopy
Assisted ventilation
Atherectomy
Austria
Autologous chondrocyte implantation
Automated external defibrillator
AV fistula
AV graft
Balloon kyphoplasty
Bariatric surgery
Baroreflex activation therapy
Barrett’s oesophagus
Belgium
Benign prostatic hyperplasia
Biopsy
Bone Conductive Hearing Device
Breast reconstruction
Bronchial thermoplasty
Burns
Caesarean section
Cancer
Capsule endoscopy
Carbon ion therapy
Cardiac ablation
Cardiac computer tomography
Cardiac pacemaker
Cardiac resynchronization therapy
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Cardiovascular devices
Cardiovascular procedures
Carotid endarterectomy
Cataract
Cell therapy
Cholecystectomy
Chronic obstructive pulmonary disease
Chronic wounds
Clinical guidelines
Cochlear implants
Commissioning
Computed tomography
Conditional reimbursement
Connected medical devices
Continuous glucose monitoring (CGM)
Coronary interventions
Coronary percutaneous revascularization procedures
Coronary procedures
Coronavirus
Coverage with evidence development (CED)
Critical care
See all tags

Two new diagnostic codes were added to private reimbursement schedule in England in July/August 2018

The Clinical Coding and Schedule Development (CCSD) develops and maintains procedural and diagnostics nomenclature for private payers in England. Once codes are added to the Schedule, a rivate insurance company can develop reimbursement tariff for these procedures and tests.

The CCSD Group has approved the following diagnostic codes for publication to the CCSD Schedule in July/August with a recommended adoption date of 1st November 2018:

  • 18S rRNA gene and Sequencing (3545G)
  • ELA2 Cyclic Neutropenia Genetic Screen (3546G)

See full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

Tags
UK
Private health insurance
Reimbursement
In-vitro diagnostic tests

The latest related news

10
Jan 2025

List of medical procedures reimbursed with restrictions updated in the Netherlands

On December 19, 2024, the Dutch Healthcare Institute (ZIN) published the updated list of medical procedures reimbursed under basic health insurance with restrictions or limitations. The procedures have the so-called "claim" codes (aanspraakcodes). The Dutch Healthcare Authority assigns the "claim" codes based on positions published by the ZIN. The changes included the introduction of one new procedure code.
Read more
08
Jan 2025

New CCAM codes to be introduced in France

On December 24, 2024, the decision of the National Union of Health Insurance Funds (UNCAM) regarding the update of the CCAM Classification of procedure codes was published in the Official Journal of the French Republic. Changes include registration of three new procedure codes, modification of billing notes for certain procedures, and amendment of modifiers. The updates are expected to come into force on February 1, 2025.
Read more
06
Jan 2025

Changes in the Belgian cervical cancer screening program from January 2025

In December 2024, the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) announced changes in the cervical cancer screening program starting from January 1, 2025. The key change is that in people aged 30 to 64 years, an HPV (Human Papillomavirus) test will be the primary for cervical cancer screening instead of a cytological examination. For this age group, HPV tests will be reimbursed every five years.
Read more
02
Jan 2025

The 2025 version of the SwissDRG released

On December 12, 2024, the entity managing the DRG system in Switzerland, SwissDRG, published the final (billing) version of the 2025 DRG system. In total, 23 new DRGs related to cardiovascular, gastrointestinal, nephrology and urology, neurology and neurosurgery, obstetrics and gynecology, orthopedics, pulmonary and airways, and some other areas were introduced. Also, 17 new add-on reimbursement categories were implemented.
Read more